Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Zepbound (semaglutide) and Mounjaro (tirzepatide) are both FDA-approved GLP-1 receptor agonist medications, yet they operate through different mechanisms that can produce different results. Mounjaro activates two hormonal pathways—GLP-1 and GIP receptors—while Zepbound targets only the GLP-1 pathway. Knowing these distinctions helps patients and their healthcare providers select the right therapy for sustainable weight management.
How Zepbound and Mounjaro Target Different Hormonal Pathways
Zepbound works by activating GLP-1 receptors in the brain and digestive system, reducing hunger signals and slowing stomach emptying. This single-pathway approach has demonstrated consistent weight loss results across multiple clinical trials. Patients using semaglutide typically experience a decrease in appetite and an increased feeling of fullness after smaller meals.
Mounjaro takes a dual-action approach by stimulating both GLP-1 and GIP receptors simultaneously. The GIP (glucose-dependent insulinotropic polypeptide) pathway adds an additional layer of metabolic regulation. This combination may explain why some patients report greater weight loss with tirzepatide compared to semaglutide alone in head-to-head studies.
Clinical Evidence: Weight Loss Outcomes and Effectiveness Rates
Zepbound demonstrated average weight loss of 15-22% of baseline body weight in clinical trials, with most patients reaching their maximum benefit over 68 weeks. The medication showed consistent tolerability and a well-understood side effect profile across diverse patient populations. Long-term data supports sustained weight maintenance when patients continue the medication.
Mounjaro produced average weight loss of 20-25% of baseline body weight in comparable trials, with some patients exceeding 25% reduction. The dual-pathway activation may contribute to these larger average reductions, though individual responses vary considerably. Both medications require ongoing use to maintain weight loss benefits, as discontinuation typically leads to weight regain.
Why Your Genetic Makeup Influences Which Medication Works Best
Not every patient responds identically to GLP-1 or GIP receptor activation, and genetic variations explain much of this difference. Key genetic variants like GLP1R rs6923761 and GIPR rs1800437 influence how effectively your body responds to each medication's mechanism of action. PlexusDx's Precision Peptide Genetic Test maps 14 pathways and 49 peptides to identify which receptor activation pattern aligns with your genetic predispositions.
A patient carrying certain GLP1R variants may experience optimal appetite suppression with semaglutide, while another person's GIPR gene expression might favor tirzepatide's dual activation. Understanding your peptide pathway genetics removes guesswork from medication selection and increases the likelihood of achieving your weight loss goals. This personalized approach transforms weight loss treatment from trial-and-error into precision medicine.
Side Effect Profiles and Tolerability Considerations
Both Zepbound and Mounjaro commonly cause gastrointestinal side effects including nausea, vomiting, and diarrhea, particularly during dose escalation. These effects typically diminish as the body adjusts over several weeks, and slower dose titration protocols can minimize initial discomfort. Muscle loss and potential gallbladder issues represent less common but serious considerations with both medications.
Individual tolerance varies significantly between patients, and some people tolerate one medication better than the other. Starting with a lower-dose formulation and gradually increasing allows your system to acclimate with fewer adverse events. PlexusDx offers multiple delivery formats including oral and microdose protocols specifically designed to improve tolerability while maintaining efficacy.
Access and Cost: How PlexusDx Compounded Options Compare
Zepbound (brand semaglutide) carries a significantly higher price when purchased through traditional retail pharmacies, often exceeding $900-1200 monthly. PlexusDx provides compounded semaglutide from licensed 503A pharmacies starting at just $149 per month, making this proven weight loss therapy accessible without insurance. All PlexusDx medications are HSA/FSA eligible, and the company serves all 50 states with no membership fees.
Mounjaro brand tirzepatide typically costs $1000-1300 monthly at retail pricing, creating a substantial financial barrier for many patients. PlexusDx's compounded tirzepatide injection starts at $249 per month, offering the advanced dual-pathway benefits at a fraction of the brand price. For patients seeking both semaglutide and tirzepatide benefits, PlexusDx also offers GLP-Squared Injection (a dual compound of both medications) starting at $249 per month—your dose may need to go up, but your price won't.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes more weight loss—Zepbound or Mounjaro?
Clinical trials show Mounjaro (tirzepatide) produces slightly greater average weight loss (20-25%) compared to Zepbound (15-22%), but individual results vary significantly based on genetics, lifestyle, and metabolism. Some patients achieve excellent results with semaglutide alone, while others benefit from tirzepatide's dual GLP-1/GIP activation. A genetic assessment through PlexusDx's Precision Peptide Genetic Test can help predict your likely response to each medication.
Can I switch from Zepbound to Mounjaro if I'm not seeing results?
Yes, many patients successfully transition between semaglutide and tirzepatide if the initial medication doesn't produce desired weight loss. The transition typically involves a washout period and gradual titration to allow your body to adjust to the new medication's mechanism. Discuss any medication change with your healthcare provider to ensure safe transition and appropriate dosing.
How much does PlexusDx compounded tirzepatide cost compared to brand Mounjaro?
PlexusDx compounded tirzepatide injection begins at just $249 per month from licensed 503A pharmacies, compared to $1000-1300 for brand Mounjaro. All PlexusDx medications are HSA/FSA eligible, require no insurance, and come with no membership fees. Your dose may increase over time, but your price remains flat at $249 monthly regardless of dose level.
Are compounded semaglutide and tirzepatide as safe as FDA-approved brands?
PlexusDx sources all compounded medications from licensed 503A compounding pharmacies that follow strict quality, sterility, and potency standards set by the FDA and state pharmacy boards. While compounded medications are not FDA-approved (only the base compounds are), 503A compounding provides equivalent safety oversight to brands. Discuss any concerns about medication sourcing with your healthcare provider.
What does the PlexusDx Precision Peptide Genetic Test reveal about my response to these medications?
The Precision Peptide Genetic Test ($99 add-on after your first month) analyzes key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 across 14 metabolic pathways and 49 peptides. These insights reveal whether your genetics favor GLP-1 activation alone (semaglutide/Zepbound) or benefit more from dual GLP-1/GIP activation (tirzepatide/Mounjaro), enabling truly personalized treatment selection.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating the Weight Loss Journey: Does Ozempic Eventually Stop Working?
How Does Mounjaro Help Blood Sugar? A Deep Dive into Dual-Action Weight Loss and Glycemic Control